Moayedifar Roxana, Shudo Yasuhiro, Kawabori Masashi, Silvestry Scott, Schroder Jacob, Meyer Dan M, Jacobs Jeffrey P, D'Alessandro David, Zuckermann Andreas
Department for Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
J Heart Lung Transplant. 2024 Apr;43(4):673-680. doi: 10.1016/j.healun.2023.12.013. Epub 2023 Dec 30.
The prevalence of end-stage heart failure and patients who could benefit from heart transplantation requires an expansion of the donor pool, relying on the transplant community to continually re-evaluate and expand the use of extended criteria donor organs. Introduction of new technologies such as the Paragonix SherpaPak Cardiac Transport System aids in this shift. We seek to analyze the impact of the SherpaPak system on recipient outcomes who receive extended criteria organs in the GUARDIAN-Heart Registry.
Between October 2015 and December 2022, 1,113 adults from 15 US centers receiving donor hearts utilizing either SherpaPak (n = 560) or conventional ice storage (ice, n = 453) were analyzed from the GUARDIAN-Heart Registry using summary statistics. A previously published set of criteria was used to identify extended criteria donors, which included 193 SherpaPak and 137 ice.
There were a few baseline differences among recipients in the 2 cohorts; most notably, IMPACT scores, distance traveled, and total ischemic time were significantly greater in SherpaPak, and significantly more donor hearts in the SherpaPak cohort had >4 hours total ischemia time. Posttransplant mechanical circulatory support utilization (SherpaPak 22.3% vs ice 35.0%, p = 0.012) and new extracorporeal membrane oxygenation/ventricular assist device (SherpaPak 7.8% vs ice 15.3%, p = 0.033) was significantly reduced, and the rate of severe primary graft dysfunction (SherpaPak 6.2% vs ice 13.9%, p = 0.022) was significantly reduced by over 50% in hearts preserved using SherpaPak. One-year survival between cohorts was similar (SherpaPak 92.9% vs ice 89.6%, p = 0.27).
This subgroup analysis demonstrates that SherpaPak can be safely used to utilize extended criteria donors with low severe PGD rates.
终末期心力衰竭的患病率以及可从心脏移植中获益的患者数量,需要扩大供体库,这依赖于移植界不断重新评估并扩大对边缘供体器官的使用。诸如Paragonix SherpaPak心脏运输系统等新技术的引入有助于这一转变。我们旨在分析SherpaPak系统对GUARDIAN-Heart注册研究中接受边缘供体器官的受者结局的影响。
2015年10月至2022年12月期间,从GUARDIAN-Heart注册研究中分析了来自美国15个中心的1113名接受供体心脏的成年人,这些成年人使用SherpaPak(n = 560)或传统冰保存法(冰保存组,n = 453),采用汇总统计数据。使用先前发表的一组标准来识别边缘供体,其中包括193例使用SherpaPak保存的供体和137例使用冰保存的供体。
两个队列的受者之间存在一些基线差异;最显著的是,SherpaPak组的IMPACT评分、运输距离和总缺血时间明显更高,并且SherpaPak队列中总缺血时间>4小时的供体心脏明显更多。移植后机械循环支持的使用率(SherpaPak组为22.3%,冰保存组为35.0%,p = 0.012)和新型体外膜肺氧合/心室辅助装置的使用率(SherpaPak组为7.8%,冰保存组为15.3%,p = 0.033)显著降低,并且使用SherpaPak保存的心脏中严重原发性移植物功能障碍的发生率(SherpaPak组为6.2%,冰保存组为13.9%,p = 0.022)显著降低超过50%。队列之间的一年生存率相似(SherpaPak组为92.9%,冰保存组为89.6%,p = 0.27)。
该亚组分析表明,SherpaPak可安全用于利用边缘供体,且严重原发性移植物功能障碍发生率较低。